Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Diabetic Nephropathy | Current Treatment | US

Login to access report north_east
Contact sales account_box

Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with high morbidity, mortality, and healthcare cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy and are unable to treat the underlying cause of the disease and prevent progressive renal decline in patients. This report investigates the current prescribing practices for DN and analyzes the various factors driving treatment decisions.

QUESTIONS ANSWERED

  • Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
  • Which attributes are most important in choosing drugs for the management of DN patients?
  • How do physicians perceive standard-of-care therapies such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for DN?
  • What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east